Drug Profile
Trastuzumab biosimilar - Reliance Life Sciences
Alternative Names: R-TPR-016; TrastuRelLatest Information Update: 15 Jan 2022
Price :
$50
*
At a glance
- Originator Reliance Life Sciences
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Breast cancer
Most Recent Events
- 28 Jan 2019 Launched for Breast cancer (Late-stage disease, Second-line therapy or greater) in India (IV)
- 12 Apr 2013 Reliance Life Sciences plans a phase III trial for Breast cancer (Late-stage disease, Second-line therapy or greater) in India (CTRI2013-04-003549)
- 11 Apr 2013 Preclinical trials in Breast cancer in India (IV)